Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

A Case Series on a Layered Biomaterial Strategy for Midface Rejuvenation: Combining Collagen Stimulators and Hyaluronic Acid

Ao YJ., Zhou YJ.

Case Report / Series on Skin Aging, Facial Rejuvenation, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
J Cosmet Dermatol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41873133
PMCID
PMC13009702
DOI
10.1111/jocd.70815

Abstract (original English)

Background The midface is a key area where aging signs first appear, involving multi-layered changes such as epidermal fine lines, volume loss leading to hollowing and sagging, and deep structural support weakening resulting in nasolabial fold deepening. Single-material treatments often fail to address this complexity comprehensively. While hyaluronic acid (HA) effectively restores volume, its impact on skin texture is limited; collagen stimulators promote long-term collagen regeneration but lack immediate shaping capability. Objective Through the presentation of six typical cases, this study aims to illustrate the clinical application of a layered treatment strategy using HA and collagen stimulators, either alone or in combination. It seeks to describe how this anatomy-based approach can address single or compound midface aging signs and provide a preliminary clinical reference for comprehensive rejuvenation. Methods This descriptive case series included six female patients with distinct midface aging phenotypes. Efficacy was assessed blindly by independent physicians using standardized scales (GAIS, Merz, Hirmand, MVDSS, WSRS). Results All cases showed improvement in target aging signs. Quantitative improvements were observed: Case 3 (infraorbital hollowing) improved from Merz Grade 2 to 1; Case 4 from Merz Grade 4 to 1; Case 5 (tear trough) improved from Hirmand Grade 2 to 0

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
FaceHumansCollagenHyaluronic AcidBiocompatible MaterialsTreatment OutcomeRejuvenationCosmetic TechniquesSkin AgingAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research